These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 35946516)
1. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma. Liu J; Nie C Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516 [TBL] [Abstract][Full Text] [Related]
2. Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway. Li X; Yin X; Bao H; Liu C Mol Cell Probes; 2023 Feb; 67():101877. PubMed ID: 36442661 [TBL] [Abstract][Full Text] [Related]
3. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
4. Exosomal miR-93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway. Bao Y; Xu S; Zhou J; Zhao C; Dai S; Zhang Y; Rao M J Biochem Mol Toxicol; 2024 Mar; 38(3):e23666. PubMed ID: 38375688 [TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway. Li Y; Ye Y; Feng B; Qi Y J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252 [TBL] [Abstract][Full Text] [Related]
6. Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma. Gong J; Yan S; Yu H; Zhang W; Zhang D Med Sci Monit; 2018 Oct; 24():7586-7594. PubMed ID: 30353907 [TBL] [Abstract][Full Text] [Related]
7. Y-box binding protein 1 augments sorafenib resistance Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628 [TBL] [Abstract][Full Text] [Related]
8. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148 [TBL] [Abstract][Full Text] [Related]
9. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis. Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling. Cheng Z; Ni Q; Qin L; Shi Y Braz J Med Biol Res; 2021; 54(9):e10390. PubMed ID: 34076140 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399 [TBL] [Abstract][Full Text] [Related]
12. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479 [TBL] [Abstract][Full Text] [Related]
13. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27. Wang D; Han S; Peng R; Jiao C; Wang X; Yang X; Yang R; Li X J Exp Clin Cancer Res; 2016 Feb; 35():37. PubMed ID: 26911146 [TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434 [TBL] [Abstract][Full Text] [Related]
15. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1. Guo XL; Wang HB; Yong JK; Zhong J; Li QH Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839 [TBL] [Abstract][Full Text] [Related]
16. microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. Jiang XM; Yu XN; Liu TT; Zhu HR; Shi X; Bilegsaikhan E; Guo HY; Song GQ; Weng SQ; Huang XX; Dong L; Janssen HLA; Shen XZ; Zhu JM Biomed Pharmacother; 2018 Sep; 105():1147-1154. PubMed ID: 30021351 [TBL] [Abstract][Full Text] [Related]
17. miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN. Liu K; Liu S; Zhang W; Jia B; Tan L; Jin Z; Liu Y Oncol Rep; 2015 Aug; 34(2):1003-10. PubMed ID: 26045065 [TBL] [Abstract][Full Text] [Related]
18. Silencing Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790 [TBL] [Abstract][Full Text] [Related]
19. Rap2B knockdown suppresses malignant progression of hepatocellular carcinoma by inactivating the PTEN/PI3K/Akt and ERK1/2 pathways. Zhu L; Sun Y; Zhang S; Wang L Mol Cell Biochem; 2020 Mar; 466(1-2):55-63. PubMed ID: 32052247 [TBL] [Abstract][Full Text] [Related]
20. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN. Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]